Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: DNA vaccines - CytoGenix

Next Previous
Drug Profile

Research programme: DNA vaccines - CytoGenix

Alternative Names: CYDBA 507; Ebola virus DNA vaccine - CytoGenix; H5N1 influenza virus vaccine - CytoGenix; HIV DNA vaccine - CytoGenix; Influenza A virus DNA vaccine H5N1 - CytoGenix; Multivalent DNA vaccine against H5N1 - CytoGenix; Pandemic flu DNA vaccine - CytoGenix; Seasonal flu DNA vaccine - CytoGenix; Smallpox DNA vaccine - CytoGenix

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CytoGenix
  • Developer CytoGenix; United States Army Medical Research Institute of Infectious Diseases
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Ebola virus infections; HIV infections; Influenza A virus H5N1 subtype; Influenza virus infections; Smallpox

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Ebola-virus-infections(Prevention) in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype(Prevention) in USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top